Roivant Sciences (ROIV) Increase (Decrease) In Litigation Settlement Receivables — Quarterly & Annual

Screener

Increase (Decrease) In Litigation Settlement Receivables at other companies

VisaV

-$1.06B—

Fidelity National Information ServicesFIS

-$19M-290%

Conagra BrandsCAG

-$100K-114%

AstronicsATRO

$0+100%

Middlesex Water CompanyMSEX

$0-100%

LON

LeonaBio, Inc.LONA

-$407K-200%

Other financials

Income statement

Revenue$1.4M-33.5%

Operating income-$366.0M-28.5%

Net income-$189.8M+15.0%

EPS (diluted)-$0.26+21.2%

Balance sheet

Cash & equivalents$77.1M-18.7%

Total debt$107.2M+7.5%

Total equity$4.2B-2.6%

Total assets$5.3B+5.4%

Cash flow

Operating cash flow-$270.5M-32.4%

CapEx$419.0K-89.6%

Free cash flow-$270.9M-30.0%

Valuation

Market cap$25.84B+239%

Enterprise value$25.87B+239%

P/S3,431.3×+3,103×

Profitability

Operating margin-9,130.5%-13,995pp

Net margin-6,079.9%-6,193pp

FCF margin-10,901%-22,382pp

Returns & leverage

Return on equity-17.1%-17.7pp

Debt / equity0×0.0×

Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept roiv:IncreaseDecreaseInLitigationSettlementReceivables.

The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026. Open the filing →

Filed: Aug 6, 2026, 7:28 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q2 2026
Accession: 0001635088-26-000090

FAQ

What is Roivant Sciences's increase (decrease) in litigation settlement receivables?: Roivant Sciences (ROIV) reported increase (decrease) in litigation settlement receivables of $1.39M in Q2 2026.
What does increase (decrease) in litigation settlement receivables mean?: Increase (Decrease) In Litigation Settlement Receivables as reported by Roivant Sciences Ltd. Common Shares.

Ask your AI about Roivant Sciences's increase (decrease) in litigation settlement receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk